Company Overview and News
LONDON, Nov. 8, 2016 /PRNewswire/ -- The agricultural micronutrients market is projected to reach a value of USD 8.05 billion by 2021, growing at a CAGR of 8.2% from 2016. The market drivers include increase in soil deficiencies, increase in demand for biofuels, macronutrients antagonism, and increase in demand for high-quality yield.
LONDON, Aug. 8, 2016 /PRNewswire/ -- The Southeast Asian & Australasian biostimulants market was valued at USD 233.8 million in 2015, and is projected to reach USD 451.8 million by 2021 The Southeast Asian biostimulants market is projected to continue its growth in the next five years. Factors such as toxicity of agrochemicals, need for environment-friendly & innovative production methods, advent of agricultural modernization, and better value for crops have turned the agricultural community's attention towards biostimulants.
LONDON, June 29, 2016 /PRNewswire/ -- The biostimulants market is projected to reach USD 2.91 billion by 2021. This market has been gaining prominence among broad-acre crops to improve the crop productivity against different stress conditions such as intense heat, drought, salinity, or floods. Factors such as raw material availability and widening applications in row crops such as cereals and oilseeds for its efficient stress response mechanism are projected to drive the biostimulants market.
The report "Biostimulants Market by Active Ingredient (Humic acids, Fulvic Acids, Seaweed, Microbials, Trace Minerals, Vitamins, and Amino acids), Application Method (Foliar, Soil, and Seed), Crop Type, & by Region - Global Trends & Forecasts to 2021", The Biostimulants Market is projected to reach USD 2.91 Billion by 2021, at a CAGR of 10.4% from 2016 to 2021.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...